Abstract | BACKGROUND:
Hemolytic uremic syndrome (HUS) can be triggered by Shiga toxin producing Escherichia coli (STEC) infection or it can be defined as atypical HUS (aHUS) if it is related to uncontrolled complement activation. aHUS is characterized by a high incidence of recurrence after kidney transplantation, and it can also occur de novo in transplant recipients. Eculizumab is used both to prevent and to treat aHUS following kidney transplantation. In this paper, we report our centre experience and we present 4 cases of HUS in patients who underwent kidney transplantation. METHODS: This is a single-center experience about HUS development in transplanted patients. RESULTS: CONCLUSION: The correct diagnosis of HUS and the identification of the complement component alterations in case of aHUS are important parameters required to predict the risk of post-transplant recurrence of the disease. In the cases we reported, eculizumab has been found to be effective both to prevent and to treat aHUS following kidney transplantation.
|
Authors | Sabrina Milan Manani, Grazia Maria Virzì, Anna Giuliani, Anna Clementi, Alessandra Brocca, Daniela Dissegna, Francesca Martino, Emanuele Stefano Giovanni d''Amore, Claudio Ronco |
Journal | Nephron
(Nephron)
Vol. 136
Issue 3
Pg. 245-253
( 2017)
ISSN: 2235-3186 [Electronic] Switzerland |
PMID | 28419995
(Publication Type: Case Reports, Journal Article, Review)
|
Copyright | © 2017 S. Karger AG, Basel. |
Topics |
- Adult
- Female
- Hemolytic-Uremic Syndrome
(complications, surgery)
- Humans
- Kidney Failure, Chronic
(complications)
- Kidney Transplantation
- Male
- Middle Aged
|